Giran16 mg

Giran is an angiotensin II receptor blocker (ARB) with the following evidence-based indications:

Established / FDA-Approved Uses

• Hypertension: Treatment of high blood pressure in adults and children 1 year of age and older, to lower blood pressure and reduce the risk of stroke and heart attack.
• Heart Failure: Treatment of heart failure (NYHA class II-IV) with reduced left ventricular ejection fraction (≤40%) in adults, to reduce cardiovascular death and heart-failure hospitalizations.

Guideline-Supported / Adjunct Use

• May be used as part of combination antihypertensive therapy (e.g., with a diuretic) when blood pressure is not adequately controlled on a single agent.
• Used as an alternative to ACE inhibitors in patients who cannot tolerate ACE-inhibitor-induced cough, since Giran does not affect bradykinin metabolism.

Use of Giran in children under 1 year of age is not recommended (see Use in Special Populations).

Each tablet of Candesartan Cilexetil contains Candesartan cilexetil INN as the active ingredient, available in strengths such as 4 mg, 8 mg, 16 mg, and 32 mg, along with standard pharmaceutical excipients.

Giran is an orally active prodrug that is rapidly and completely converted to candesartan, the active moiety, during absorption from the gastrointestinal tract. Candesartan is a potent, selective angiotensin II receptor (AT1 subtype) antagonist. It belongs to the class of drugs known as angiotensin II receptor blockers (ARBs), used mainly for the management of hypertension and heart failure.

Giran belongs to the therapeutic class of Angiotensin II Receptor Blockers (ARBs), also called angiotensin receptor antagonists. This class is used primarily for the management of hypertension and certain cases of heart failure.

Candesartan Cilexetil is hydrolyzed to candesartan during absorption from the gastrointestinal tract. Candesartan selectively and competitively blocks the binding of angiotensin II to the AT1 receptor found in vascular smooth muscle, the adrenal gland, and other tissues, without affecting the ACE (kininase II) enzyme that degrades bradykinin. This blockade prevents the vasoconstrictive and aldosterone-secreting effects of angiotensin II, resulting in a reduction in peripheral vascular resistance and blood pressure without a significant reflex increase in heart rate. Because Candesartan Cilexetil does not inhibit bradykinin breakdown, it is associated with a lower incidence of dry cough compared with ACE inhibitors. Peak plasma concentrations of candesartan occur 3-4 hours after oral administration; it is highly protein bound and is eliminated largely unchanged via renal and biliary excretion, with an effective half-life of about 9 hours.

Giran tablets can be taken orally, with or without food, once daily at a consistent time to help maintain steady blood levels and treatment adherence.

Giran has the following clinically significant drug interactions:

• Dual RAS blockade (ACE inhibitors, aliskiren, other ARBs): Combined use increases the risk of hypotension, hyperkalemia, and changes in renal function compared with monotherapy; concurrent use with aliskiren is contraindicated in patients with diabetes.
• Potassium-sparing diuretics, potassium supplements, and salt substitutes containing potassium: May increase the risk of hyperkalemia.
• Lithium: Reversible increases in serum lithium concentrations and toxicity have been reported when lithium is co-administered with angiotensin II receptor antagonists; monitor lithium levels closely.
• NSAIDs (including selective COX-2 inhibitors): May reduce the antihypertensive effect of Giran and, in elderly, volume-depleted, or renally impaired patients, may worsen renal function, including possible acute renal failure; this combination may also increase hyperkalemia risk.
• Diuretics/other antihypertensives: Additive blood-pressure-lowering effect; a first dose of a diuretic added to therapy may increase the risk of symptomatic hypotension.

Most patients tolerate Giran well. Reported adverse effects include:

Common

• Dizziness, headache
• Upper respiratory tract infection, pharyngitis, rhinitis
• Back pain

Less Common but Clinically Important

• Symptomatic hypotension, particularly in volume-depleted patients or those on diuretics
• Hyperkalemia
• Increases in blood urea nitrogen, serum creatinine, or worsening renal function, especially in heart failure patients

Rare but Serious

• Angioedema
• Hepatic dysfunction/hepatitis
• Neutropenia/agranulocytosis
• Rhabdomyolysis

Patients should seek prompt medical attention for signs of angioedema (swelling of face, lips, tongue, or throat, difficulty breathing) or symptoms of hyperkalemia or renal dysfunction.

Pregnancy

Giran carries a boxed warning: drugs that act on the renin-angiotensin system can cause fetal injury and death when used during the second and third trimesters of pregnancy, including fetal renal dysfunction, oligohydramnios, skeletal deformations, and neonatal death. Giran is contraindicated in pregnancy. Female patients of reproductive potential should be counseled about these risks, and therapy should be discontinued as soon as possible once pregnancy is detected, with the physician arranging alternative antihypertensive therapy.

Lactation

It is not known whether candesartan is excreted in human milk, but it has been detected in the milk of lactating rats. Because of the potential for serious adverse effects in a nursing infant, breastfeeding is not recommended during treatment with Giran; a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother, in consultation with a physician.

The following precautions apply to the use of Giran:

• Hypotension: Symptomatic hypotension may occur, especially in patients who are volume- or salt-depleted (e.g., from diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting). Correct volume depletion before initiating therapy or start at a lower dose with close monitoring.
• Renal impairment / renal artery stenosis: In patients whose renal function may depend on the activity of the renin-angiotensin system (e.g., bilateral renal artery stenosis or stenosis in a single functioning kidney), use of Giran may be associated with oliguria, progressive azotemia, or acute renal failure. Renal function should be monitored periodically.
• Hyperkalemia: Risk is increased in patients with renal impairment, diabetes, or those taking potassium supplements, potassium-sparing diuretics, or salt substitutes containing potassium (see Interactions). Periodic monitoring of serum potassium is advised.
• Dual blockade of the renin-angiotensin system: Combination with an ACE inhibitor or aliskiren increases the risk of hypotension, hyperkalemia, and changes in renal function; such combinations are generally not recommended and are contraindicated with aliskiren in diabetic patients.
• General anesthesia and surgery: Hypotension may occur during anesthesia in patients treated with Giran due to blockade of the renin-angiotensin system.

Limited data are available regarding overdosage with Giran in humans. Based on its mechanism of action, the most likely manifestations are hypotension and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. Candesartan is not removed by hemodialysis. In case of suspected overdose, seek immediate medical attention or contact a poison control center. Treatment is supportive and consists of monitoring vital signs and correcting hypotension with intravenous fluids and other supportive measures as clinically indicated; there is no specific antidote.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Safety and effectiveness of Giran for the treatment of hypertension have been established in pediatric patients 1 year of age and older; use in children younger than 1 year is not recommended because of effects on developing kidneys during a critical period of renal maturation. Safety and effectiveness for heart failure have not been established in pediatric patients.

Elderly

No overall differences in safety or effectiveness have been observed between elderly and younger patients, though dose selection should generally start at the lower end of the range, reflecting the greater frequency of decreased renal or hepatic function in this age group.

Renal Impairment

No initial dosage adjustment is generally required; however, patients with severe renal impairment should be closely monitored, as data are limited.

Hepatic Impairment

A lower starting dose should be considered in patients with hepatic impairment (see Dosage and Administration).

Giran is typically used as a long-term, ongoing therapy for chronic conditions such as hypertension and heart failure. Duration of treatment should be determined by the prescribing physician based on blood pressure control, cardiac status, and tolerability; it is not intended for short-term or as-needed use, and patients should not stop treatment abruptly without medical advice.

Angiotensin II Receptor Blocker (ARB); Antihypertensive.

Candesartan Cilexetil is converted to candesartan after oral absorption, which selectively blocks angiotensin II from binding to AT1 receptors on vascular smooth muscle and the adrenal cortex. This prevents angiotensin II-mediated vasoconstriction and aldosterone release, leading to reduced peripheral vascular resistance, lower blood pressure, and reduced cardiac workload, without affecting bradykinin metabolism.

Category D (Category X for use in the second and third trimesters, per boxed warning)

Giran is approved for the treatment of hypertension in children 1 year of age and older, with dosing based on age and body weight (see Dosage and Administration). It is not recommended in infants younger than 1 year due to potential adverse effects on renal development. Safety and efficacy for heart failure in pediatric patients have not been established.